ERBB2 and neoplasm: In line with this, targeting the pathways closely upstream or downstream of Shc1 (e.g., ErbB2, EGFR, MEK, ERK, PTEN, PI3K) by drugs or molecular manipulation has been shown to enhance anti-tumor immune responses in various studies, as discussed later.